“On 7th Oct 2024, Singapore HSA updated Guidance for Post-Marketing Vigilance Requirements for Therapeutic Products & Cell, Tissue and Gene Therapy Products. The changes are summarised as below:
– Removed fax
Regulatory News
Singapore HSA Updates Guidance Documents for CTGTP
In September/October 2024, HSA has re-organized and updated Cell, Tissue or Gene Therapy Product (CTGTP) guidance on Product Notification, Product Registration and Variation Application.
To view the updated guidance, please visit
FDA Philippines Publishes General Rules and Regulations on the Registration of Pharmaceutical Products and Active Pharmaceutical Ingredients Intended for Human Use
Administrative Order 2024-0013 establishes updated rules for the registration of pharmaceutical products and Active Pharmaceutical Ingredients (APIs) for human use, aligning with regional and global regulatory harmonization efforts. The Order
Singapore HSA Updates Webpage on Nitrosamine Impurities in Medicines
Singapore Health Sciences Authority (HSA) has updated the webpages on nitrosamine impurities in medicines.
The main webpage provides general information on the background and the regulatory approach on the nitrosamine impurities
Singapore HSA Updates Therapeutic Products Guidances
As part of HSA’s ongoing initiative to improve regulatory efficiency and enhance clarity in Singapore’s regulatory requirements and processes, HSA updates Main Guidance on Therapeutic Product Registration and Appendices (with
New Refuse-to-File Mechanism for Pharmaceutical Registrations in Hong Kong Effective July 1, 2024
The Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee has announced the implementation of a Refuse-to-File (RTF) mechanism for initial pharmaceutical product registration
Singapore HSA Updates Guidance for Post-Marketing Vigilance Requirements for Therapeutic Products & CTGTP
On 1st April 2024, Singapore HSA updated Guidance for Post-Marketing Vigilance Requirements for Therapeutic Products & Cell, Tissue and Gene Therapy Products. The updates mainly involved the following aspects:
Risk
Malaysia NPRA Updates Guideline for Application of Clinical Trial Import License (CTIL) and Clinical Trial Exemption (CTX)
Malaysia NPRA has revised the Malaysian Guideline for Application of Clinical Trial Import License (CTIL) and Clinical Trial Exemption (CTX) Edition 8.0, slated for publication on April 30, 2024.
This decision
Singapore HSA Updates Labelling Guideline for Therapeutic Products
On 28th March 2024, HSA revises “Appendix 7: Points to Consider for Singapore Labelling of the Guidance on Therapeutic Product Registration in Singapore”. The guidance has been updated to include